The generic name of Endo is recombinant human vascular endothelial inhibitor injection, which is not a chemotherapeutic drug, it is only a kind of clinically used drug for the treatment of non-small cell lung cancer. Recombinant human vascular endothelial inhibitor injection is a kind of vascular-targeted drug for tumors, and this drug has become an important adjuvant drug in the standard first-line treatment for advanced non-small cell lung cancer in China in the combination chemotherapy. The main component of this drug is recombinant human vascular endothelial inhibitor, which is derived from the fermentation product of E. coli engineered bacterium, and it is a kind of intravenous injection, which has good efficacy in the treatment of initial or recurrent stage III/IV non-small cell carcinoma by combination chemotherapy. However, this drug may cause mild fatigue, chest tightness, panic, diarrhea, liver function abnormality, and skin maculopapular rash in a few patients after application, and it should be used with caution in cardiotoxicity and renal insufficiency. This drug should be standardized under the guidance of a doctor to avoid the risks caused by blind use.